Integrin-Linked Kinase Signaling in Cancer Biology

Integrin-Linked Kinase (ILK) occupies a central position within focal adhesions, acting as a scaffold that couples extracellular matrix engagement to intracellular cascades governing cell survival, proliferation, migration and invasion. Although originally classified as a serine/threonine kinase, its catalytic activity remains controversial, and ILK is now widely regarded as a pseudokinase that orchestrates signal transduction through assembly of the IPP complex (ILK–PINCH–Parvin). Through recruitment of adaptor and effector proteins, ILK modulates key nodal pathways such as Akt/Protein Kinase B and GSK3β, thereby influencing cell cycle progression, apoptosis resistance and the epithelial-to-mesenchymal transition. Dysregulation of ILK expression or localisation contributes to tumour growth, metastatic dissemination and remodelling of the tumour microenvironment, rendering it an attractive candidate for targeted intervention across diverse cancer types.

Research from Nature Portfolio

Recent studies have elucidated a non-catalytic mechanism by which ILK regulates cytoskeletal dynamics and cell adhesion. Structural and biochemical analysis revealed that ILK, in complex with PINCH and Parvin, engages actin-binding motifs to bundle F-actin filaments in a process sensitised by Mg-ATP bound to the pseudokinase domain. Disruption of this mechanism impairs stress fibre formation and migration, underlining ILK’s role as a force transducer within focal adhesions. In glioma models, investigation of Ras Suppressor-1 (RSU-1), a matrix adhesion protein, demonstrated that its interaction with ILK and downstream STAT6 phosphorylation determines invasive potential in aggressive versus non-aggressive cell lines. Silencing RSU-1 in highly invasive glioma cells reduced STAT6 activation and matrix metalloproteinase expression, highlighting ILK-mediated adaptor functions in driving tumour invasiveness.

Integrin-Linked Kinase Signaling in Cancer Biology publication trend

The graph below shows the total number of articles in integrin-linked kinase signaling in cancer biology across all publications each year (not limited to Nature Index journals).

Technical terms

Integrin-Linked Kinase (ILK): A focal adhesion scaffold protein that recruits adaptor molecules to transduce signals from integrins to intracellular pathways.

IPP complex: The tripartite assembly of ILK, PINCH and Parvin that organises cytoskeletal and signalling interactions at adhesion sites.

Pseudokinase: A catalytically inactive kinase-like domain that functions as a structural mediator rather than an enzyme.

Epithelial-to-Mesenchymal Transition (EMT): A cellular programme enabling epithelial cells to acquire migratory, invasive mesenchymal properties during cancer progression.

Focal adhesion: A multiprotein assembly linking extracellular matrix receptors (integrins) to the actin cytoskeleton and signalling networks.

References

1. Integrin-linked kinase (ILK): the known vs. the unknown and perspectives. Cellular and Molecular Life Sciences (2022).
2. Non-catalytic signaling by pseudokinase ILK for regulating cell adhesion. Nature Communications (2018).
3. Ras suppressor-1 (RSU-1) promotes cell invasion in aggressive glioma cells and inhibits it in non-aggressive cells through STAT6 phospho-regulation. Scientific Reports (2019).
4. α-Parvin Expression in Breast Cancer Tissues: Correlation with Clinical Parameters and Prognostic Significance. Cells (2024).
5. Combination Effects of Integrin-linked Kinase and Abelson Kinase Inhibition on Aberrant Mitosis and Cell Death in Glioblastoma Cells. Biology (2023).
6. Comprehensive Analyses and Immunophenotyping of LIM Domain Family Genes in Patients with Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences (2023).